Next month in Las Vegas, the Neuromod Prize, a $9.8 million competition to accelerate the development of targeted neuromodulation therapies, will host a finalist showcase at HLTH 2025, a convening of over 12,000 healthcare innovation leaders. This session will feature presentations from Phase 3 teams, followed by a live winner announcement. Join us at the Plutus Startup Stage (part of the Investor Connect Lounge) at 4:30 p.m. on Monday, October 20, to hear from the Phase 3 teams as they showcase their groundbreaking solutions and find out the Phase 3 winners of the Neuromod Prize.
Get to know the Phase 3 teams
Phase 3 participants have conducted IDE-enabling studies using diverse approaches to stimulate a range of targets, including the spinal, sacral, pelvic, and vagus nerves. Throughout Phase 3, the competition has provided technical assistance and additional resources to help teams accelerate and develop their solutions as they compete for a share of the $5 million Phase 3 prize pool.
Meet the Phase 3 participants:
- Anthony F. DiMarco, M.D. – High-frequency spinal cord stimulation reduces respiratory tract infections and improves bowel management in people with neurological impairment
- Juniper Biomedical – Highly precise, micro-implantable neuromodulation to treat stress urinary incontinence, overactive bladder and fecal incontinence
- University of Louisville Research Foundation Inc. – StimXS, neuromodulation of the lumbosacral spinal cord, automatically regulates cardiovascular, respiratory, and urinary systems after spinal cord injury
- University of Pittsburgh Department of Urology – A novel multi-channel implantable device for sacral-pudendal neuromodulation to treat bladder, bowel, and sexual disorders
These innovative solutions demonstrate the ability to independently regulate two or more desired autonomic functions without unintended effects on non-target organs. By supporting promising solutions that precisely target the spinal, sacral, pelvic, and vagus nerves, this NIH SPARC competition bridges the gap between early-stage research and clinical use, accelerating the path from bench to bedside.
Register to attend HLTH 2025 and make plans to join us in Las Vegas. We look forward to seeing you there!
Accelerating the development of targeted neuromodulation therapies
The Neuromod Prize is a SPARC (Stimulating Peripheral Activity to Relieve Conditions) initiative from NIH that is accelerating the development of targeted neuromodulation therapies. Proposed solutions needed to be tunable, accurate, and precise, and to demonstrate an ability to quantitatively assess and control multiple on-target and related off-target effects.
To receive updates, including the winner announcement, subscribe to the Neuromod Prize newsletter.